The microrna deregulation in Colorectal Cancer / Yong Fung Lin
Colorectal cancer (CRC) is the carcinoma of the colon and rectum in the gastrointestinal system. CRC is the third most common cancer in men and the second in women worldwide. The limitations of the currently available biomarkers and technologies for CRC screening and surveillance have highlighted...
| Main Author: | |
|---|---|
| Format: | Thesis |
| Published: |
2014
|
| Subjects: | |
| Online Access: | http://studentsrepo.um.edu.my/4586/ http://studentsrepo.um.edu.my/4586/1/Thesis_hardcover_YONG_FUNG_LIN.pdf |
| Summary: | Colorectal cancer (CRC) is the carcinoma of the colon and rectum in the gastrointestinal
system. CRC is the third most common cancer in men and the second in women
worldwide. The limitations of the currently available biomarkers and technologies for
CRC screening and surveillance have highlighted the necessity of finding novel
biomarkers. Recently, microRNA (miRNA)-based studies have rendered remarkable
contribution in the elucidation of mechanisms of carcinogenesis. miRNAs are short,
non-coding RNA molecules that act as regulators of gene expression through messenger
RNA (mRNA) degradation or translational inhibition. Blood miRNA expression
profiles offer great potential as non-invasive biomarkers. In the present study, the aims
were to characterise and correlate the tissue and blood miRNA expression patterns of
primary CRC patients, and establish the functional roles of the identified miRNAs in the
carcinogenesis of CRC. Firstly, the miRNA profiling study was divided into two phases:
(I) marker discovery by miRNA microarray using paired cancer tissues (n = 30) and
blood samples (CRC, n = 42; control, n = 18); (II) marker validation by reverse
transcription-quantitative real-time polymerase chain reaction (RT-qPCR) using an
independent set of paired cancer tissues (n = 30) and blood samples (CRC, n = 70;
control, n = 32). Logistic regression and receiver operating characteristic curve analyses
were applied to obtain diagnostic utility of the miRNAs. Seven miRNAs (miR-150,
miR-193a-3p, miR-23a, miR-23b, miR-338-5p, miR-342-3p and miR-483-3p) were
found to be differentially expressed in both tissue and blood samples. Significant
positive correlations were observed in the tissue and blood levels of miR-193a-3p, miR-
23a and miR-338-5p. These miRNAs were demonstrated as a classifier for CRC
detection, with a receiver operating characteristic curve area of 0.887 (80.0% sensitivity,
84.4% specificity and 83.3% accuracy). Next, these miRNAs were subjected to
functional and miRNA:mRNA target validation studies via miRNA mimics and
iv
inhibitors transfections. SW480 and SW620 CRC cell lines were utilised. Cell viability,
apoptosis, migration and invasion assays were conducted. Luciferase assays were
performed for the validation of target mRNAs. The expression levels of target mRNAs
and proteins in clinical CRC samples and cell lines were assessed using RT-qPCR and
Western blot. miR-193a-3p was identified to be involved in CRC cell migration and
invasion by targeting FOXO4. miR-23a was determined to possess apoptosis resistance
function by targeting APAF1. However, the transfection of miR-338-5p did not reveal
significant findings in the cell viability, apoptosis, migration and invasion analyses. In
conclusion, miRNA deregulation in the blood is reflective of that in the CRC tissue. The
triple miRNA classifier of miR-193a-3p, miR-23a and miR-338-5p may serve as
potential blood biomarkers for CRC detection. The miRNA:mRNA target validation
studies have highlighted the potential application of miR-193a-3p:FOXO4 and miR-
23a:APAF1 regulation axes in miRNA-based therapy and prognostication. |
|---|